Suchergebnisse - "Rota-Scalabrini, Delia"

PubPharm (50)

1

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

enthalten in: Blood | 2024

von D'Agostino, M. | Bertuglia, G. | Rota-Scalabrini, D. | +22

CommentIn: Blood. 2024 Feb 15;143(7):564-566. - PMID 38358852

2

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

3

A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents

enthalten in: Haematologica | 2023

von Mina, R. | Petrucci, M. | Bonello, F. | +23

4

Prospective evaluation of minimal residual disease in the phase II FORTE trial : a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

enthalten in: EClinicalMedicine | 2023

von Oliva, S. | Genuardi, E. | Paris, L. | +22

5

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

enthalten in: EClinicalMedicine | 2023

von Zamagni, E. | Oliva, S. | Gay, F. | +28

6

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma : pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

enthalten in: The Lancet. Oncology | 2023

von Mina, R. | Musto, P. | Rota-Scalabrini, D. | +24

ErratumIn: Lancet Oncol. 2023 Feb;24(2):e72. - PMID 36725151

7

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Bertamini, L. | Oliva, S. | Rota-Scalabrini, D. | +26

CommentIn: J Clin Oncol. 2022 Sep 20;40(27):3099-3102. - PMID 35759726

8

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE) : a randomised, open-label, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Gay, F. | Musto, P. | Rota-Scalabrini, D. | +23

9

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma : the phase II, multi-arm, randomized UNITO-EMN10 trial

enthalten in: Blood cancer journal | 2021

von Mina, R. | Falcone, A. | Bringhen, S. | +25

10

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD : final results of FIL HD0801 trial

enthalten in: Blood advances | 2021

von Ricardi, U. | Levis, M. | Evangelista, A. | +26

1
2
3
4
5
Nächster »
[5]